Who
Gil M. Labrucherie
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Septerna; Director, Rezolute; CFO and CBO, Acelyrin; SVP, COO & CFO, Nektar Therapeutics.
In numbers
- Trades disclosed
- 212
- Buys
- 7
- Sells
- 58
- Bought
- $629K
- Sold
- $29.2M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 2 Apr 2007
- Last trade
- 6 Feb 2026
- Last filed
- 10 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Feb 2026filed 10 Feb 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 7 Aug 2025filed 11 Aug 2025 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 10 Jun 2025filed 13 Jun 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 10 Jun 2025filed 13 Jun 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 27 Feb 2025filed 27 Feb 2025 | SEPN SepternaBiotechnology | SEC FORM 4 Bought | $22K3,718 at $5.85 | filing |
| 25 Feb 2025filed 27 Feb 2025 | SEPN SepternaBiotechnology | SEC FORM 4 Bought | $35K6,282 at $5.59 | filing |
| 21 Feb 2025filed 21 Feb 2025 | SEPN SepternaBiotechnology | SEC FORM 4 Bought | $29K5,000 at $5.85 | filing |
| 20 Feb 2025filed 21 Feb 2025 | SEPN SepternaBiotechnology | SEC FORM 4 Bought | $85K14,500 at $5.88 | filing |
| 19 Feb 2025filed 21 Feb 2025 | SEPN SepternaBiotechnology | SEC FORM 4 Bought | $58K10,500 at $5.51 | filing |
| 16 Feb 2025filed 20 Feb 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 16 Feb 2025filed 20 Feb 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —25,500 at $0.00 | filing |
| 7 Feb 2025filed 7 Feb 2025 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —222,000 at $0.00 | filing |
| 31 Aug 2024filed 4 Sep 2024 | Acelyrinoption or derivative | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 23 May 2024filed 24 May 2024 | Acelyrinoption or derivative | SEC FORM 4 Code A | —184,042 at $0.00 | filing |
| 23 Jan 2024filed 25 Jan 2024 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jan 2024filed 11 Jan 2024 | Acelyrinoption or derivative | SEC FORM 4 Code A | —855,513 at $0.00 | filing |
| 4 Oct 2023filed 6 Oct 2023 | Acelyrin | SEC FORM 4 Code J | —40,763 at $0.00 | filing |
News
Septerna (NASDAQ:SEPN) COO Sells $149,640.00 in StockSEPN · dailypolitical.com · 20 Oct 2026Nektar Therapeutics (NASDAQ:NKTR) Research Coverage Started at Leerink PartnersNKTR · tickerreport.com · 15 Oct 2026Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor HyperinsulinismRZLT · manilatimes.net · 14 Oct 2026Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink PartnersNKTR · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Gil M. Labrucherie; 4 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.